Novartis news from FierceBioResearcher
NewsCancer drugs should be tailored to fit patient
In a study that may change the way that cancer drugs are developed and prescribed, a research group composed of Roche scientists and doctors at the prestigious Brigham and Women's Hospital in Boston Read more...
Novartis bankrolls a drug manufacturing revolution
With the help of a $65 million contribution from Novartis, scientists at MIT are launching a 10-year program aimed at revolutionizing the way drugs are manufactured. At the heart of the project is Read more...
| Press ReleasesNew data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants New data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants Data in JAMA show Menveo may provide infants protection against four of the most common Read more... PRESS RELEASE: Novartis launches strategic initiative to improve competitiveness in a changing healthcare environmenT Novartis launches strategic initiative to improve competitiveness in a dynamically changing healthcare environment "Forward" to simplify organizational structures, accelerate and Read more... PRESS RELEASE: Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration Collaboration efforts will focus on the discovery and optimization of antibodies against a significant Read more... PRESS RELEASE: Tasigna gains European approval for patients with a life-threatening form of leukemia who are resistant or intol Tasigna® gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies Tasigna produced response in 49% of patients with Read more... PRESS RELEASE: Antisoma Shares Slide as Novartis Corporation (NVS) Sets up Avastin Fight Antisoma Shares Slide as Novartis Corporation Sets up Avastin Fight LONDON--Nov 20, 2007 -- ASA404 phase III lung cancer trial to include broader range of patients London, UK: 20 November 2007 - Read more... |
Get more Novartis coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets